Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2~* Participant has relapsed/refractory disease (received at least one prior therapy)~* Diagnosis of CLL that meets published 2008 Modified International Workshop on CLL National Cancer Institute - Working Group (IWCLL NCI-WG) Guidelines and:~  * has an indication for treatment according to the 2008 Modified IWCLL NCI-WG Guidelines~ * has clinically measurable disease (lymphocytosis \> 5 × 10\^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam)~ * with or without 17p deletion or TP53 mutation~ * may have been previously treated with a prior B-cell receptor inhibitor therapy~* Adequate bone marrow function~Exclusion Criteria:~* Participant has developed Richter's transformation or Prolymphocytic leukemia (PLL)~* Participant has previously received venetoclax~* History of active malignancies other than CLL within the past 2 years prior to first dose of venetoclax, with the exception of:~  * adequately treated in situ carcinoma of the cervix uteri~ * adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin~ * previous malignancy confined and surgically resected (or treated with other modalities) with curative intent~* Active and uncontrolled autoimmune cytopenias (within 2 weeks prior to screening), including autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP), despite low dose corticosteroids~* Prior allogeneic stem cell transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Venetoclax (Type: EXPERIMENTAL): Venetoclax was administered orally once daily (QD) for a planned duration of up to 2 years or until disease progression; median time on treatment was 127 weeks. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).